Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they will attack the tumour and provide an effective treatment against it.

Injecting a preparation that stimulates these T Cells effectively vaccinates the patient against the tumour providing immediate treatment and longer term protections against it. The Oxford Vacmedix technology – the Recombinant Overlapping Peptides – is a powerful preparation that delivers just this result .

Overlapping peptides have been found to be very effective in providing treatment for cervical cancer in early work (Ref Kenter et al.,New England Journal of Medicine, 2009, 361: 1838 – 1847). These materials had to be produced synthetically making them both expensive and hard to produce consistently. The patented Recombinant Overlapping approach produces a much more effective which is both simpler and more economical to produce.